http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0170236-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d595ec481a2a081fed4aa2fd4ff52d8 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-655 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-655 |
filingDate | 2001-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8912b6e0758f8b7fa6e28f2f29cd66b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfc9532c893cf70a904614c68c748334 |
publicationDate | 2001-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | WO-0170236-A1 |
titleOfInvention | Preventing and/or treating diabetes mellitus |
abstract | The present invention demonstrates a method for inhibiting O-linked protein glycosylation in a tissue or cell, comprising the step of contacting said tissue or cell with (Z)-1-[N-(3-Ammoniopropyl)-N-(n-propyl)amino] diazen-ium-1,2-diolate or a derivative thereof. The present invention is also directed to a method of treating or inhibiting the onset of diabetes mellitis in an individual in need of such treatment, comprising the step of administering to said individual a pharmacological dose of a compound which inhibiting O-linked protein glycosylation in a tissue or cell of said individual. Further, the present invention provides a pharmaceutical composition, comprising (Z)-1-[N-(3-Ammoniopropyl)-N-(n-propyl)amino] diazen-ium-1,2-diolate and a pharmaceutically acceptable carrier or a derivative thereof. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006072171-A1 |
priorityDate | 2000-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 110.